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ABSTRACT
Maternal vaccination to induce anti-HIV immune factors in breast milk is a potential intervention to prevent postnatal HIV-1
mother-to-child transmission (MTCT). We previously demonstrated that immunization of lactating rhesus monkeys with a
modified vaccinia Ankara (MVA) prime/intramuscular (i.m.) protein boost regimen induced functional IgG responses in milk,
while MVA prime/intranasal (i.n.) boost induced robust milk Env-specific IgA responses. Yet, recent studies have suggested that
prevention of postnatal MTCTmay require both Env-specific IgA and functional IgG responses in milk. Thus, to investigate
whether both responses could be elicited by a combined systemic/mucosal immunization strategy, animals previously immu-
nized with theMVA prime/i.n. boost regimen received an i.n./i.m. combined C.1086 gp120 boost. Remarkably, high-magnitude
Env-specific IgA responses were observed in milk, surpassing those in plasma. Furthermore, 29% of vaccine-elicited Env-specific
B cells isolated from breast milk were IgA isotype, in stark contrast to the overwhelming predominance of IgG isotype Env-spe-
cific B cells in breast milk of chronically HIV-infected women. A clonal relationship was identified between Env-specific blood
and breast milk B cells, suggesting trafficking of that cell population between the two compartments. Furthermore, IgA and IgG
monoclonal antibodies isolated from Env-specific breast milk B cells demonstrated diverse Env epitope specificities andmultiple
effector functions, including tier 1 neutralization, antibody-dependent cellular cytotoxicity (ADCC), infected cell binding, and
inhibition of viral attachment to epithelial cells. Thus, maternal i.n./i.m. combined immunization is a novel strategy to enhance
protective Env-specific IgA in milk, which is subsequently transferred to the infant via breastfeeding.
IMPORTANCE
Efforts to increase the availability of antiretroviral therapy to pregnant and breastfeeding women in resource-limited areas have
proven remarkably successful at reducing HIV vertical transmission rates. However, more than 200,000 children are infected
annually due to failures in therapy implementation, monitoring, and adherence, nearly half by postnatal HIV exposure via ma-
ternal breast milk. Intriguingly, in the absence of antiretroviral therapy, only 10% of breastfed infants born to HIV-infected
mothers acquire the virus, suggesting the existence of naturally protective immune factors in milk. Enhancement of these protec-
tive immune factors throughmaternal vaccination will be a critical strategy to reduce the global pediatric AIDS epidemic. We
have previously demonstrated that a high magnitude of HIV Env-specific IgA in milk correlates with reduced risk of infant HIV
acquisition. In this study, we describe a novel HIV vaccine regimen that induces potent IgA responses in milk and therefore
could potentially protect against breast milk HIVMTCT.
More than 200,000 new pediatric human immunodeficiencyvirus (HIV) infections occur annually via mother-to-child
transmission (MTCT), nearly half through breastfeeding (1). An-
tiretroviral (ARV) drugs can dramatically reduce the rate of
MTCT, but in areas of high HIV prevalence, acute HIV infection
in pregnant and postpartum women as well as poor access and
adherence to ARV treatment throughout the breastfeeding period
has limited progress in the prevention of breast milk transmission
(2). According to UNAIDS in 2014, only 68% of HIV-infected
pregnant women in low- and middle-income countries received
ARV therapy during pregnancy, and only 61% of those women
continued this therapy postpartum (3). Despite the risk of HIV
acquisition, breastfeeding is necessary for infant survival in many
regions of the world, as breastfed infants have lower rates of diar-
rheal and respiratory infections (4). It is well established that an-
tibodies are transferred to infants via the placenta and through
breast milk consumption (5); thus, maternal immunization could
Received 22 February 2016 Accepted 24 February 2016
Accepted manuscript posted online 2 March 2016
Citation Nelson CS, Pollara J, Kunz EL, Jeffries TL, Jr, Duffy R, Beck C, Stamper L,
Wang M, Shen X, Pickup DJ, Staats HF, Hudgens MG, Kepler TB, Montefiori DC,
Moody MA, Tomaras GD, Liao H-X, Haynes BF, Ferrari G, Fouda GGA, Permar SR.
2016. Combined HIV-1 envelope systemic and mucosal immunization of lactating
rhesus monkeys induces a robust immunoglobulin A isotype B cell response in
breast milk. J Virol 90:4951–4965. doi:10.1128/JVI.00335-16.
Editor: G. Silvestri
Address correspondence to Sallie R. Permar, sallie.permar@dm.duke.edu.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
crossmark
May 2016 Volume 90 Number 10 jvi.asm.org 4951Journal of Virology
be an important alternative strategy to allow safe breastfeeding in
areas of high HIV prevalence.
The specificity and function of antibodies important to prevent
mucosal HIV transmission remain unclear. Despite the high level
of total IgA in breast milk, the predominant envelope (Env)-spe-
cific antibody response in the breast milk of both HIV-infected
women and simian immunodeficiency virus (SIV)-infected rhe-
susmonkeys is IgG (6, 7). The presence of high levels of functional
IgG in breast milk, particularly IgG mediating antibody-depen-
dent cellular cytotoxicity (ADCC), has been linked to reduced
incidence of MTCT (8). Env-specific IgG in breast milk is likely
due to transudate from the systemic compartment, since HIV
Env-specific IgG responses in breast milk correlate well with those
in plasma, though they are lower by two orders of magnitude (6).
Interestingly, themajority of Env-specific B cells in the breastmilk
of chronically HIV-infected women produce IgG and not IgA (9,
10). Indeed, it has traditionally proven to be exceedingly difficult
to induce Env-specific IgA or IgA isotype B cells in the mucosal
compartment via vaccination (11), and thus the potential role of
IgA in preventing viral transmission at the mucosal surface is
poorly understood.
The RV144 ALVAC/AIDSVAX vaccine efficacy trial in Thai-
land, which demonstrated 31.2% efficacy, suggested a deleterious
role of plasma Env-specific IgA responses of certain specificities in
protection against sexually transmitted HIV infections (12). Fur-
ther analysis revealed an inverse correlation between ADCC activ-
ity and acquisition risk in vaccinees with low IgA responses (12). It
was hypothesized that IgA blocks ADCC by competing for the
same binding sites as ADCC-mediating IgG antibodies. Indeed,
vaccine-elicited IgA specific for conformational epitopes in the C1
region of Env can block ADCC activity in clinical samples (13).
Nevertheless, there is solid evidence that mucosal IgA could con-
tribute to the prevention of HIV transmission. In a recent study,
vaccine-elicited mucosal IgA responses were associated with pro-
tection against vaginal simian-human immunodeficiency virus
(SHIV) challenge (14), and multiple investigations have demon-
strated that passive rectal immunizationwith neutralizing dimeric
IgA can protect from subsequent SHIV exposure (15, 16). Simi-
larly, we recently reported an association between a high magni-
tude of Env-specific IgA and low rates of breast milk HIV trans-
mission (17). Thus, Env-specific IgA responses in the systemic and
mucosal compartments seem to play dramatically different phys-
iologic roles.
In previous studies, we demonstrated thatHIV vaccination can
elicit strong Env-specific antibody responses in milk of rhesus
monkeys (18). Hormonally induced lactating animals were im-
munized with the transmitted/founder Env C.1086 using either a
gp140 DNA or modified vaccinia Ankara (MVA) prime followed
by two C.1086 gp120 protein boosts delivered either systemically
(intramuscularly [i.m.]) or mucosally (intranasally [i.n.]). The
systemic andmucosal vaccine regimens elicited comparable levels
of plasma Env-binding IgG, yet mucosal immunization induced
significantly higher Env-binding IgA responses in breast milk.
Furthermore, systemic vaccination induced a much more potent
functional IgG response (tier 1 neutralization, ADCC) in breast
milk than mucosal vaccination. An optimal vaccine regimen for
the prevention of breast milk transmissionmay need to elicit both
strong Env-binding and functional antibody responses in milk
(19).
Thus, we sought to design a vaccine strategy that could com-
bine the potent functional antibody response observed in the sys-
temically vaccinated animals with the robust Env-specific IgA re-
sponse in the mucosally vaccinated animals. Animals previously
immunized with the C.1086 MVA prime/i.n. boost regimen re-
ceived an additional simultaneous i.n./i.m. protein boost. Env-
binding and functional responses were then assessed in both
plasma and breast milk. To examine the antibody responses in
more detail, B cells fromboth blood andmilkwere isolated,VH/VL
genes sequenced, and IgA and IgGmonoclonal antibodies (MAbs)
analyzed for specificity and associated function. This study pro-
vides a detailed understanding of the antibody-mediated immune
responses elicited by combined systemic andmucosal vaccination,
enabling critical assessment of this maternal vaccination strategy
for the prevention of HIV-1 breast milk transmission.
MATERIALS AND METHODS
Animals and vaccine regimen.RecombinantMVAexpressing theC.1086
Env gp140 gene and recombinant Env gp120 glycoproteins was generated
as described previously (18). Lactation was induced in 4 female Indian
rhesus monkeys by depot medroxyprogesterone and estradiol injections
followed by oral dopamine antagonist administration as described previ-
ously (20). The lactating monkeys were initially primed with 109 PFU of
recombinant MVA (rMVA) expressing the HIV C.1086 Env gene and
boosted twice intranasally (i.n.) at weeks 12 and 16 with 200 g of HIV
C.1086 gp120 protein (100 g in each nostril) adjuvanted with the Toll-
like receptor 7/8 (TLR7/8) agonist R848 (500g/animal) (Fig. 1). The i.n.
boosted animals were immunized a third time with a combined i.n./i.m.
boost technique at week 50 following the original MVA prime. The i.n.
component of the combined boostwas identical to the previous i.n. boosts
(200 g HIV Env C.1086 gp120 plus 500 g R848). The intramuscular
(i.m.) component of the combined boost consisted of 100 g HIV Env
C.1086 gp120 and 250 l of the adjuvant STR8S-C (squalene-containing
STS base adjuvant plus R848 plus oCpGs) (21). i.n. protein boosts were
administered to anesthetized monkeys placed on their backs in 30-l
aliquots at 30-s intervals for a total volume of 150 l per nostril (22).
Between aliquot administrations, the nares were held closed. The i.m.
protein boost was administered at a single injection site in the quadriceps
of anesthetizedmonkeys. Blood samples were collectedweekly for 4weeks
following immunization and then bimonthly for an additional 1 to 2
FIG 1 Combined i.n./i.m. HIV-1 Env vaccine regimen. Lactation was hor-
monally induced in four female rhesus macaques prior to weeks 0, 12, and 50
so that milk samples could be collected at each time point. Animals were
primed with recombinant MVA expressing HIV Env C.1086 gp140 and then
boosted twice with HIV Env C.1086 gp120 i.n. with R848 adjuvant. The ani-
mals were then boosted a third time using a combined i.n./i.m. Env boost with
C.1086 gp120 i.n. plus R848 adjuvant as well as C.1086 gp120 i.m. plus
STR8S-C adjuvant.
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months. Milk was collected twice weekly by manual collection (20) and
then separated into cellular, supernatant, and lipid fractions by centrifu-
gation (7, 23). Animals were maintained according to the Guide for the
Care and Use of Laboratory Animals (grants.nih.gov), and the animal pro-
tocol was approved by the Duke University Animal Care and Use Com-
mittee.
Plasma, milk, and MAb HIV-1 Env recombinant protein ELISA.
Env-binding IgG and IgA were assessed for plasma/milk (18) and for
monoclonal antibodies (MAbs) (24). For plasma/milk assays, 384-well
enzyme-linked immunosorbent assay (ELISA) plates were coated over-
nightwithHIVC.1086 gp120 (30 ng/well) and then blockedwith the assay
diluent (phosphate-buffered saline [PBS] containing 4% whey, 15% nor-
mal goat serum, and 0.5% Tween 20). Dilutions of plasma or milk were
then added to the plates. Antibodies were detected with a horseradish
peroxidase (HRP)-conjugated polyclonal goat anti-monkey IgG (Rock-
land, Gilbertsville, PA) or IgA (Rockland, Gilbertsville, PA) and the addi-
tion of the ABTS-2 peroxidase substrate system (KPL, Gaithersburg,
MD).Macacamulatta purified IgG and IgA (Nonhuman Primate Reagent
Resource) were used to develop standard curves, and the concentration of
IgG or IgA antibody was calculated relative to the standard using a 5-pa-
rameter fit curve (WorkOut 2.5; PerkinElmer, Waltham, MA). For re-
combinant MAb ELISA, 384-well ELISA plates (Corning Life Sciences,
Lowell, MA) were coated with each antigen at 30 ng/well. Antigens in-
cluded C.1086 gp120 D7 and A1.con env03 gp140 (12), B.con env03
gp140 (12), C.con env03 gp140 (12), AE.A244 gD gp120 (12), C.1086
V1V2, C.1086 V2, C.1086 V1V2 N156Q, and gp70 B.CaseA2 V1V2 (18),
gp70 B.CaseA2 V1V2/169K (18), C.con env03.V3 linear peptide and
BioRV144 C1 peptide (13), C.YU2 core, C.YU2 core D368R, RSC3 (25),
RSC3 d371/P363N (25), and C.1086 D7 gp120 K160N, ConC gp120, and
ConC gp120 N332A. Serial dilutions of monoclonal antibody were dis-
tributed to the plates after blocking, and the MAbs were detected using a
peroxidase-conjugated goat anti-monkey IgG (Rockland, Gilbertsville,
PA) and the SureBlue Reserve tetramethylbenzidine (TMB) peroxidase
substrate (KPL, Gaithersburg, MD). For monoclonal antibodies, the 50%
effective concentration (EC50) was calculated by the concentration of an-
tibodywhich resulted in a 50% reduction in optical density (OD) from the
maximum value.
Quantitative SIgA ELISA. ELISA plates (Corning Life Sciences, Low-
ell, MA) were coated overnight at 4°C with Con6 gp120 B. Dilutions of
breast milk were added to the plate following blocking. The antibodies
were detected using anti-secretory-chain IgA Ab SC 9H7 CL3 (a mouse-
derived monoclonal IgG2A kappa antibody which cross-reacts with rhe-
sus and human secretory components [SCs] though does not react with
dimeric IgA alone) (kindly provided by Barton Haynes), followed by an
HRP-conjugated polyclonal anti-mouse IgG (Promega, Madison, WI)
and then TMB peroxidase substrate. The standard used was b12 secretory
IgA (SIgA) prepared by complexing b12 dimeric IgA (dIgA) (NHP re-
agent program), with rhesus SC followed by an overnight incubation,
resulting in a 1:1 molar ratio of dIgA to SC. The concentration of HIV-1
Env-specific SIgA antibody was calculated relative to the standard curve
using a 5-parameter fit curve (WorkOut 2.5; PerkinElmer, Waltham,
MA). A positive result was defined as the mean OD of preimmune milk
samples plus 3 standard deviations (SD). The limit of detection (LOD) in
this assay was determined to be 100 ng/ml based upon the lowest concen-
tration of the dIgA-SC standard with a correspondingOD that exceeded 3
times that of the blank wells.
sCD4 andA32 blocking ELISA.Assessment of antibody specificity for
the CD4bs and C1 conformational epitopes was done as described previ-
ously (24). Briefly, 384-well plates were coated overnight with C.1086
gp120 (30 ng/well) and then blocked before addition of serially diluted
MAbs. For the soluble CD4 (sCD4) blocking ELISA, sCD4 (a gift from
Bing Chen) was next added to the plates (6.4 ng/well), followed by addi-
tion of a biotinylated anti-CD4 (0.3 ng/well). For the A32 blocking ELISA,
biotinylated A32 antibody was added (0.625 ng/well). In both assays,
HRP-conjugated streptavidin (at a 1:30,000 dilution) and SureBlue Re-
serve TMB peroxidase substrate were used to detect the biotinylated an-
tibodies. Background was normalized using negative-control wells that
received only assay diluent in place of primary monoclonal antibody.
Percent inhibition was calculated as follows: 100  (serum triplicate
mean/no-inhibition control mean) 100. A reduction of absorbance by
50%by aMAb indicated blocking of sCD4 binding to gp120 or blocking
of A32 MAb binding to the C1 region (26).
TNCELISA.A384-well plate was coatedwith 2g/ml of anti-tenascin
C (anti-TNC) antibody rabbit polyclonal IgG (H-300; Santa Cruz Bio-
technology) and incubated at 4°C overnight.Wells were washed with PBS
plus 0.1% Tween 20 and blocked with 7.5% bovine serum albumin (BSA)
(Gibco) at room temperature for 1 h.Milk samples delipidized by centrif-
ugation at 21,000  g were diluted in 7.5% BSA, and a commercially
available purifiedTNC (Millipore)was used as the protein standard, rang-
ing from5g/ml to 5 ng/ml. The standards and sampleswere added to the
plate and incubated for 1 h at room temperature. Plates were washed 2
times, and 1 g/ml of tenascin C mouse monoclonal antibody (T2H5;
Fisher) was added and incubated for 1 h at room temperature. Plates were
washed 2 times, and a 1:10,000 dilution of goat anti-mouse HRP-conju-
gated antibody (Promega) was added to each well and incubated for 1 h at
room temperature. Plates were washed 4 times, and SureBlue Reserve
TMB microwell substrate (KPL) was added and incubated in the dark at
room temperature for 5 min. TMB stop solution (KPL) was added, and
plates were read at 450 nm.
Peptide array serum specificitymapping. Serum epitopemapping of
heterologous strains was performed as described previously with minor
modifications (27, 28). In short, a peptide library of overlapping peptides
(15-mers overlapping by 12), covering 7 full-length HIV-1 gp160 Env
consensus sequences (clades A, B, C, and D, group M, CRF1, and CRF2)
and 6 vaccine and laboratory strain gp120 sequences (A244_1, TH023_1,
MN_B, 1086_C, TV1_C, and ZM651_C), was printed onto epoxy glass
slides (provided by JPT Peptide Technologies GmbH [Germany]). Se-
quences of all peptides in the library have been previously reported (29).
Microarray binding was performed using the HS4800 Pro Hybridization
Station (Tecan, Männedorf, Switzerland). All arrays were blocked with
blocking buffer (PBS, 1% milk, 5% normal goat serum [NGS], 0.05%
Tween 20) for 1 h at 30°C, followed by a 2-h incubation at 30°C with
serum diluted 1:50 in blocking buffer. Arrays were subsequently incu-
bated for 45 min at 30°C with goat anti-human IgG conjugated with
AF647 (Jackson ImmunoResearch, PA) (0.75 g/ml final concentration)
diluted with blocking buffer. Washes between all steps were with PBS
containing 0.1% Tween 20. Arrays were scanned at a wavelength of 635
nm using an Axon Genepix 4300 scanner (Molecular Devices, Sunnyvale,
CA, USA) at a photomultiplier tube (PMT) setting of 580 and 100% laser
power. Images were analyzed using Genepix Pro 7 software (Molecular
Devices). The intensity of binding of the postimmunization serum to each
peptide was corrected with its own background value, which was defined
as the median signal intensity of the prebleed serum for that peptide plus
3 times the standard errors among the 3 subarray replicates present on
each slide.
Neutralization. Neutralization of clade C tier 1 (C.MW965) and au-
tologous tier 2 (C.1086) HIV-1 pseudovirus variants by plasma,milk, and
isolated MAbs was measured in TZM-bl cells via a reduction in luciferase
reporter gene expression (30). In brief, dilutions of plasma,milk, orMAbs
were incubated with an optimized amount of virus for 45min at 37°C in a
96-well plate, and then freshly trypsinized TZM-bl cells in growth me-
dium were added to each well. Following a subsequent 48-h incubation,
the culture medium was removed and replaced with a luciferase reagent
(Bright-Glo; Promega), causing cell lysis and luminescence proportional
to the amount of infection. The luminescence was measured using a Vic-
tor 2 luminometer (PerkinElmer). The 50% inhibitory dilution (ID50)
titers were calculated as the dilution that resulted in a 50% reduction in
relative luminescence units (RLU) compared to virus control wells. Like-
wise, the 50% inhibitory concentration (IC50) values were calculated as
the concentration of antibodywhich caused a 50% reduction in RLU (31).
HIV Env-Specific IgA Isotype B Cells in Breast Milk
May 2016 Volume 90 Number 10 jvi.asm.org 4953Journal of Virology
MAbs that mediated tier 1 virus neutralization were further screened
against a multiclade panel of tier 1 viruses B.BaL.26, B.MN.3, and
B.SF162.
ADCC.TheADCCactivity of plasma, delipidized breastmilk, purified
IgG, and MAbs was assessed using the GranToxiLux (GTL) assay (32).
Briefly, CEM.NKRCCR5 cells (NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH; from Alexandra Trkola) (33) were used as targets
after coating with recombinant C.1086 gp120 protein (5 g/ml). Cryo-
preserved human peripheral blood mononuclear cells (PBMC) from an
HIV-seronegative donor with the heterozygous 158F/V genotype for Fc-
gamma receptor IIIa were used as the source of the effector cells (34).
Serial dilutions of plasma, milk, purified IgG, and MAbs were tested. The
maximum percent granzyme B (GzB) activity was defined as the peak
proportion of cells positive for proteolytically active GzB out of the total
viable target cell population. The final results are expressed after subtrac-
tion of the background percent GzB activity observed in wells containing
effector and target cells in the absence of antibodies. ADCC endpoint
titers and concentrations were determined by interpolating the dilutions
of plasma and breast milk, or the concentrations of purified antibodies,
that intersect the positive cutoff using GraphPad Prism software version
6.0f (GraphPad Software, Inc., La Jolla, CA).
ADCC inhibition. For studies with spiked breast milk (see Fig. 8), a
1:16 dilution of breast milk was spiked with previously determined opti-
mal ADCC concentrations of either DH532 (10 g/ml) or a mixture of
ADCC-mediating antibodies (A32, 2G12, 7B2, and CH44 at 15 ng/ml).
The results are reported as ADCC activity (percent granzyme B activity)
and percent ADCC inhibition, calculated as the percentage of ADCC ac-
tivity reduction based on the ADCC mediated by the IgG MAb or MAb
mixture in prevaccination milk.
Isolation of C.1086 Env-specific B cells. The C.1086 Env-specific B
cell population was identified in blood, breast milk, and gastrointestinal
(GI) tissue of all 4 monkeys via flow cytometry. Data were collected using
the FACSAria2 instrument (BDBiosciences) with the FACSDiVa software
and were analyzed by manual gating with FlowJo software. The complete
gating strategy for the total B cell populationwas defined as CD3CD14
CD16 CD20. The total numbers of identified B cells from blood and
breast milk of each monkey were as follows: A6E030, 81,191 and 1,383;
A6E042, 73,258 and 97; A6E088, 107,300 and 248; andAU71S, 34,859 and
14. Env-specific B cells were obtained from B cell population by conjuga-
tion of C.1086 Env to dyes AF647 and Pac-Blue (Invitrogen) and selection
for double-positive B cells.
MAb genetic characterization and small-scale testing. Following B
cell sorting, the expressed Ig VH and VL genes were amplified by reverse
transcription and nested PCR as described previously (35–37). The PCR
products were purified and sequenced. Ig isotype was determined by se-
quence homology. Somatic hypermutation frequencies, inferred V(D)J
rearrangement, and CDR3 length were determined from Clonalyst (40).
Overlapping PCR was performed to coexpress the variable-region PCR
products with full-length IgG1 (heavy chain) and kappa or lambda (light
chain) cassettes, and the PCR products were transiently transfected in
293T cells without the need for a cloning step. The supernatants of trans-
fected cells were screened for reactivity against the following HIV Env
proteins by small-scale ELISA: C.1086 gp140, C.10868 gp120, M.ConS
gp120, B.MNgp120, A.9004SS gp120,M.ConS gp140, A.92RW020 gp140,
B.BxB/Bal gp140, andC.CH505TFqODwV3. Six IgA and six IgG antibod-
ies were selected for large-scale production based upon (i) the strength of
binding to the immunogen gp120 region (those with higher OD against
gp140 construct were excluded) and (ii) broad clade binding specificity.
Heavy and light chains for the 12 MAbs selected were cloned into the
pcDNA3.1mammalian expression vector. The heavy chain for all anti-
bodies, including IgA, included an IgG backbone. Plasmids were tran-
siently transfected into 293F cells, and the antibody was purified using
protein A beads as described previously (35).
Epithelial cell binding. The ability of breast milk Env-specific MAbs
to impede infectious virus binding to colonic epithelial cells was assessed
(24). In short, colonic HT-29 cells (ATCC) were grown to confluence on
a 96-well flat-bottom plate in modified McCoy’s 5A medium supple-
mented with 10% FBS and antibiotics. The HT-29 cells were washed once
with serum-free medium and treated with 100 l of 50 g/ml mitomycin
C for 1 h to prevent further division, followed by two washes. The isolated
MAbs then were diluted in serum-freemedium, incubated with 10 con-
centrated HIV pseudovirus MW965 for 1 h at 37°C, added in quadrupli-
cate to the colonic epithelial cell monolayer, and then finally incubated at
37°C for 4 h. Monolayers were washed twice with PBS to remove free
virus, and 104 TZM-bl reporter cells were added to each well of the virus-
bound monolayer. After 48 h, luciferase reagent (Bright-Glo; Promega)
was added to thewell, and theRLUweremeasured. Percent inhibitionwas
calculated by dividing the RLU of each well by the median RLU of epithe-
lium-bound virus that was not preincubatedwith isolated rhesus Abs. The
IgG isoform of the influenza virus MAb CH65 was used as a negative
control, whereas the IgG isoformof broadly neutralizingCD4 binding site
MAb VRC01 was used as a positive control. The cutoff value was deter-
mined by the mean plus 2 SD of CH65 IgG relative to no antibody.
Binding of MAbs to infected cells. The ability of MAbs to recognize
CEM.NKRCCR5 infected with a C.1086 infectious molecular clone (IMC)
was assessed (32). CEM.NKRCCR5 cells were infected with a C.1086 IMC
that encodes the Renilla luciferase reporter gene and preserves all HIV-1
open reading frames (38) using dextran-DEAE as described previously
(32). At 48 h postinfection, the ability of MAbs to recognize the HIV-
infected cells wasmeasured by indirect surface immunofluorescence anal-
ysis. The infected CEM.NKRCCR5 cells were incubated with 10 g/ml of
the rhesus-derivedMAbs in R10medium for 2 h at 37°C and then stained
with a vital dye (Live/Dead Fixable Aqua Dead Cell Stain; Invitrogen) to
exclude nonviable cells from subsequent analyses. Primary Ab binding
was detected by secondary labeling with fluorescein isothiocyanate
(FITC)-conjugated goat anti-rhesus IgG (SouthernBiotech Inc., Birming-
ham, AL), and HIV-1-infected cells were identified by staining for intra-
cellular expression of p24 (KC57-RD1; Beckman Coulter) using standard
methods. Infected cell binding was evaluated by gating on live, p24
events using FlowJo version 9.8 software (TreeStar, Inc., Ashland, OR).
IgG purification and concentration. IgG was isolated from plasma
and breast milk using protein G columns (6) (protein G resin prepacked
into 96-well depletion plates [GEHealthcare]). Plasma was diluted 2-fold
with Tris-buffered saline (TBS) (pH 7.5), and 200l of the diluted sample
was added per well. For breastmilk, 300l of undiluted sample was added
to each well. The plates were incubated at room temperature, with shak-
ing, for 1 h. The unbound fractions were removed by centrifugation at
700 g for 3 min. Wells were then washed 3 times with 400 l of TBS to
remove loosely bound material. The IgG bound to the resin was eluted
with 200 l of 2.5% glacial acetic acid (pH 2.51) and immediately neu-
tralized with 120 l of 1 M Tris-HCl (pH 9.0). The eluted IgG fractions
were concentrated using Amicon Ultra centrifugal filters (Millipore) with
a 30,000-molecular-weight cutoff. The sample volume was reduced to 50
l by centrifugation at 14,000 g in a microcentrifuge precooled to 4°C.
A buffer exchange was then performed using 2.0 volumes of PBS, pH 7.5.
The concentrated IgG was assayed for protein concentration using a
NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific) using the
IgG reference setting and then diluted to 1 mg/ml with PBS.
Statistical methods. Exact Wilcoxon signed rank tests were per-
formed for all outcome and time point comparisons described in the text.
R software version 2.141.1 was used for calculations (R Foundation for
Statistical Computing, Vienna, Austria). Note that 0.13 is the lowest P
value attainable with 4 experimental animals.
RESULTS
Combined i.n./i.m. Env immunization increases Env-specific
IgA responses in breast milk. In an attempt to elicit both func-
tional IgG and Env-specific IgA responses in breast milk, four
female Indian rhesus monkeys previously immunized with an
MVA prime/i.n. boost regimen were boosted a third time with a
Nelson et al.
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combined i.n./i.m. approach 50 weeks after the original MVA
prime (Fig. 1). Lactation was hormonally induced in the rhesus
monkeys prior to immunization (20). In both plasma andmilk we
observed an increase in Env-specific IgA over the response follow-
ing i.n. Env boost alone. This increase was more pronounced in
milk yet was not statistically significant (median milk IgA after
boosts 2 and 3, 1,712 ng/ml and 7,641 ng/ml, respectively; P 
0.13) (Fig. 2). The magnitude of the Env-specific IgA response
elicited in breast milk following i.n./i.m. boost is remarkable and
distinct from that found in chronically HIV-infected individuals,
as median breast milk Env-specific IgA levels exceeded those in
plasma (median milk IgA 7,641 ng/ml and plasma IgA 6,200
ng/ml; P  0.13). Interestingly, the vaccine-elicited antibody re-
sponses were quite durable over the 34 weeks prior to i.n./i.m.
boost 3 (week 50), with high-magnitude Env-specific IgG and IgA
measured in the breast milk of vaccinated monkeys prior to the
final boost. We next investigated what proportion of the vaccine-
elicited Env-specific IgA response was secretory (SIgA) by assess-
ing the amount of secretory component in milk (Fig. 2B). Due to
sample limitation after the third protein boost, SIgA in the breast
milk was measured only preimmunization and following boosts 1
and 2. Env-specific SIgA was detected in 3 of 4 animals following
i.n. boost 2, comprising only 9% of the total Env-specific IgA in
breast milk (median IgA  1,712 ng/ml and SIgA  152 ng/ml;
P 0.13). This finding suggests that the majority of vaccine-elic-
ited Env-specific IgA did not traffic to the breast milk compart-
ment via poly-Ig receptor interaction. Thus, the predominance of
vaccine-elicited Env-specific IgA antibodies in milk was likely
either passively transcytosed through mammary epithelia or
produced locally. The vaccine-elicited IgA responses in other
mucosal compartments were also assessed. Following i.n./i.m. im-
munization, Env-binding IgA increased in the vaginal compart-
ment, surpassing levels previously attained following i.n. Env
boosts (18). There was no detectable IgA in rectal secretions (Fig.
2C and D).
High proportion of Env-specific IgA isotype memory B cells
isolated from breast milk of i.n./i.m. Env-immunized lactating
monkey A6E030. Env-specific B cells were isolated from blood,
FIG 2 The combined i.n./i.m. HIV-1 Env boost enhances IgA responses in mammary and vaginal compartments over those elicited by i.n. boost alone. The
gp120-specific IgG responses of animals given the MVA prime/i.n. boost regimen plus the combined i.m./i.n. boost are shown for plasma/milk (A) and
vaginal/rectal secretions (C), while gp120-specific IgA responses are shown for plasma/milk (B) and vaginal/rectal secretions (D). Data points represent mean
value for 4 animals, with standard deviations indicated by error bars. Plasma is in red, milk in blue, vaginal secretions in green, and rectal secretions in purple.
The secretory IgA (SIgA) fraction of the gp120-specific IgA responses is in turquoise (B). IgA was not detectable in rectal secretions for any time point.
HIV Env-Specific IgA Isotype B Cells in Breast Milk
May 2016 Volume 90 Number 10 jvi.asm.org 4955Journal of Virology
milk, and intestinal tissue using a fluorescently labeledC.1086 Env
probe (data not shown). Populations of Env-specific B cells were
identified in the blood and intestines of all four animals, compris-
ing an average of 0.12% and 0.11% of all B cells isolated in each
respective compartment. Two animals had low B cell counts in
breast milk (100 total CD20 cells). However, intriguingly, in
the remaining two animals with a significant population of breast
milk B cells, 2.64% on average were Env specific (Table 1). Based
upon the large number of breast milk B cells in monkey A6E030,
this animal was selected for investigation of the vaccine-elicited
Env-specific breast milk B cell repertoire. In total, 33 Env-specific
B cells were isolated from blood and 28 from breast milk. The
isotype distribution of the blood Env-specific MAbs was 97% IgG
and 3% IgA (Fig. 3E). In contrast, 29% of Env-specific MAbs in
the breast milk compartment were IgA, whereas 68% were IgG
and 3% IgM (Fig. 3F). This relatively high proportion of IgA-
producing B cells in milk suggests that i.n./i.m. vaccination may
induce localization of Env-specific IgA isotype B cells to themam-
mary compartment. A similar analysis was conducted for breast
milk B cells isolated from animal A6E088; however, only 5 Env-
specific B cells were isolated from blood and 5 from breast milk.
Though it is difficult to draw conclusions from the small number
ofMAbs isolated fromA6E088, 20% (1 of 5) of Env-specific B cells
were IgA isotype in both blood and breast milk
The i.n./i.m. Env vaccine regimen increases both the magni-
tude and breadth of the systemic Env epitope-specific IgG re-
sponse. To determine the impact of our immunization regimen
on the fine specificity of the plasma IgG response, we used a pep-
tide array assay to assess binding to overlapping linear peptides
covering 7 consensus strains and 6 vaccine strains of Env gp160.
The magnitude and breadth of the IgG response against Env pep-
tides increased following each vaccination (Table 2). In all ani-
mals, anti-V3 binding was the dominant response observed; how-
ever, all vaccinated animals also developed binding responses to
other linear regions, includingC1, C2, V3, C4, andC5. The animal
with the highest-magnitude IgG response (A6E030) developed
notable epitope breadth with binding responses against all these
regions. The greatest increase in gp120 peptide binding magni-
tude was seen following the first i.n. Env boost, as evidenced in the
two animals for which the preimmune and i.n. boost 1 time points
TABLE 1 Percentages of Env-specific memory B cells isolated from
blood, milk, and intestines of four i.n./i.m. Env-vaccinated lactating
monkeys
Animal
C.1086 B cells (%) in:
Blood Milk Intestine
A6E030 0.27 2.46 0.07
A6E042 0.06 NDa 0.07
A6E088 0.10 2.82 0.22
AU71S 0.06 ND 0.07
Avg 0.12 2.64b 0.11
a ND, none detected (CD20 total cell count of100).
b Average excluding values not detected due to low total CD20 cell count.
FIG 3 Isolation of C.1086 Env-specific IgA-producing B cells from breastmilk of animal A6E030. (A and B) Env-specific B cells were isolated by selection of cells
from blood (A) and milk (B) that are double positive for C.1086 Env labeled with two different fluorophores. (C and D) All MAbs isolated from Env-specific B
cells in blood (C) and breast milk (D) were confirmed to be gp120 specific by ELISA. (E and F) While the blood gp120-specific MAbs were predominantly IgG
isotype (E), those in milk were 29% IgA isotype (F). An identical analysis was performed for animal A6E088, though only 5 MAbs were isolated from plasma B
cells and 5 MAbs from breast milk B cells.
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were measured. However, the i.n./i.m. Env boost introduced ro-
bust epitope expansion in all animals, with the exception of mon-
key AU71S.
Combined i.n./i.m. Env boost increases neutralizing activity
in breast milk but does not elicit ADCC responses. We previ-
ously observed that systemic (i.m.) Env immunization, but not
mucosal (i.n.) immunization, was able to elicit neutralizing and
ADCC-mediating responses in the breast milk of lactating rhesus
macaques (18). Thus, we measured these functional antibody re-
sponses following combined i.n./i.m. Env immunization in both
TABLE 2 i.n./i.m. vaccine regimen increases both linear epitope magnitude and breadth of systemic gp120-specific IgG responses
HIV Env epitope
(peptide range, aa)
Signal intensitya for the indicated monkey and time point
A6E030 A6E042 AU71S A6E088
Prime i.n.1 i.n.2 i.n./i.m.3 Prime i.n.1 i.n.2 i.n./i.m.3 i.n.2 i.n./i.m. 3 i.n.2 i.n./i.m.3
C1.1 (28–29) 1 94 2,369 13,162 1 1 1 1 50 46 264 1,472
C1.2 (32–36) 1 10 2,128 7,091 1 1 3,646 22,843 37 21 4,558 20,443
C2.1 (83–84) 1 42 1,115 4,050 1 1 62 347 17 4 43 39
C2.2 (91) 1 6,599 7 31,884 1 501 18,187 18,831 15 205 43 7,344
V3 (93–106) 6,115 41,303 50,112 65,186 4,321 60,998 57,211 60,520 18,498 22,535 54,913 57,958
V4 (126–127) 168 207 11,719 9,690 1 1 1 1 162 102 471 649
C4 (136–139) 1,671 2,361 31,085 47,253 1 232 1 113 7,846 7,153 562 313
V5 C5 (147–151) 1 472 3,155 8,040 1 1 721 293 106 29 9,176 13,172
C5.1 (156–159) 1 6,594 24,739 23,126 1 115 504 1,610 68 164 6,153 10,711
gp41 ID (187–196) 96 781 524 1,495 1 56 1 512 597 518 117 114
MPER (212–216) 1 1 1 1 1 1 1 1 111 56 8 4
a Maximum binding (signal intensity) to a single peptide within each identified epitope. Italic, signal intensity of 1,000 to 10,000; bold italic, signal intensity of 10,000 to 30,000;
underlined bold italic, signal intensity of30,000. Plasma samples for the postprime and post-i.n. boost 1 time points were not available for animals AU71S and A6E088 due to
sample limitation.
FIG 4 Functional HIV-1 Env-specific antibody responses elicited inmilk and plasma following combined i.n./i.m. Env immunization. (A and B) Neutralization
responses against the tier 1 clade C virus MW965 in TZM-bl cells in plasma (A) and milk (B). Each colored line represents a different vaccinated animal. (C and
D) ADCC activity against HIV-1 C.1086 gp120-coated CEM.NKR cells in plasma (C) and milk (D) following the combined i.n./i.m. Env boost. The dashed line
indicates the starting dilution. Four of four animals had detectable ADCC activity in plasma, compared to zero of four animals with detectable activity in breast
milk.
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plasma andbreastmilk (Fig. 4). In each vaccinated, lactatingmon-
key, the neutralization response against a tier 1 clade C variant,
MW965, was augmented inmilk following the combined i.n./i.m.
Env boost (median ID50s after boosts 2 and 3, 226 and 702, respec-
tively; P 0.13) (Fig. 4B). Surprisingly one animal (A6E030) had
comparable neutralization activity in plasma and breast milk
(ID50s of 5,974 and 4,796, respectively). The plasma of all animals
demonstratedADCCantibody responses, which is consistentwith
results seen in the MVA prime/i.n. boost group prior to adminis-
tration of the i.n./i.m. combined boost (18). ADCC responses
were enhanced in plasma following the i.n./i.m. boost (median
titers after boots 2 and 3, 5,994 and 81,498, respectively; P 0.13)
(Fig. 4C). However, no ADCC activity was detectable in breast
milk following the i.n./i.m. boost.
The concentration of TNC does not increase in response to
vaccination. Tenascin C (TNC) is an innate protein found in
breast milk, which we have previously described to have HIV-1
neutralizing function (39). Thus, we investigated whether an in-
crease in innate factors like tenascin C might play a role in the
enhanced neutralization titers following each immunization ob-
served in this study. However, measurement of breast milk TNC
concentration across time points of the immunization schedule
revealed that while TNC was detectable in rhesus monkey milk, it
was comparable between all 4 animals and 4 time points (Table 3).
We have previously found that the concentration of TNC in hu-
man breast milk ranges from 2.2 to 671g/ml and that TNC has a
neutralization IC50 of 82 to 158 g/ml (39). Therefore, the low
level of tenascin C detected in the vaccinated monkey breast milk
across all time points (0.53 to 3.94 g/ml) suggests that the se-
quential increase in neutralization titers throughout the vaccine
schedule is not due to a change in the composition of innate breast
milk factors.
Genetic characteristics of IgA and IgGMAbs produced from
breast milk and blood Env-specific memory B cells. Genetic
analysis of paired heavy and light chains from Env-specific blood
and breast milk B cells was conducted using Cloanalyst to deter-
mine the utilizedVH andVL genes, complementarity-determining
region 3 (CDR3) length, and mutation frequency (40). Interest-
ingly, we identified a B cell clonal lineage spanning the systemic
and mammary compartments (Fig. 5). This clonal lineage was
comprised of 8 IgG MAbs, including 6 from blood and 2 from
breast milk, which strongly suggests trafficking of vaccine-elicited
Env-specific IgG isotype B cells between the two compartments.
We found that theVH4 gene family was predominant in blood and
breast milk compartments (66% of all MAbs). Themedian heavy-
chain CDR3 (HCDR3) length and mean percent VH mutation
frequencywere 15 amino acids (aa) and 5% in blood and 13 aa and
5% in breast milk. Among the 28 MAbs isolated from A6E030
breast milk B cells, the median HCDR3 length and mean percent
VHmutation frequencywere 9 aa and 5% for IgA but 15 aa and 5%
for IgG (Table 4). From these 28 milk MAbs, 6 IgA and 6 IgG
MAbs were selected for subsequent study based on themagnitude
and breadth of the Env-binding profile following transient trans-
fection. The HCDR3 length and percent VH mutation frequency
of the 6 IgA and 6 IgG MAbs selected were representative of the
total breast milk MAb population (Table 5).
i.n./i.m. Env vaccine-elicited IgA and IgG MAbs isolated
from breast milk B cells have variable Env epitope specificity.
First, the Env-binding breadth of the 6 IgA and 6 IgG antibodies
chosen for large-scale production was examined by ELISA using
TABLE 3 The concentration of innate HIV-neutralizing factor tenascin
C in breast milk does not significantly change during the vaccination
schedule
Animal
Tenascin C concn (g/ml) at time point:
Postprime Post-boost 1 Post-boost 2 Pre-boost 3
A6E030 0.53 1.47 1.37 2.47
A6E042 0.91 1.92 0.90 3.94
A6E088 1.30 0.66 2.69 2.22
AU71S 3.62 2.81 3.19 NAa
a NA, sample not available.
FIG 5 Clonal relationship of vaccine-elicited Env-specific blood and breast milk IgG isotype B cells. (A) A clonal lineage comprising monoclonal antibodies
isolated from C.1086 Env-specific blood and breast milk B cells was identified in animal A6E030 following combined i.n./i.m. immunization. UCA, unmutated
common ancestor. (B) Heavy-chain genes, HCDR3 length, and mutation frequency were determined for pairings using Cloanalyst.
Nelson et al.
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consensus clade A, B, C, and AE gp140 proteins. As anticipated,
the vaccine-elicited breast milk MAbs showed highest binding
strength to clade C Env proteins; however, 8 of the 12 MAbs
boundEnv proteins ofmultiple clades (Fig. 6). Next, epitope spec-
ificity of the MAbs was evaluated against a panel of Env peptides.
Individual IgA MAbs showed strong binding to the V2 (DH527,
EC50 0.002 g/ml), C1 (DH529, EC50 0.014 g/ml), and C4
(DH525, EC50  0.028 g/ml) regions. Additionally, one IgG
MAb was specific for V3 linear peptide (DH535, EC50  0.07
g/ml) (Fig. 6). To determine whether any of the breast milk
MAbs were specific for the CD4-binding site, binding to YU2 core
gp120 alongside the CD4-binding site-specific mutant (YU2
D368R)was assessed. One IgA and two IgG vaccine-elicitedMAbs
demonstrated strong binding to the wild-type YU2 core but not to
the YU2D368Rmutant (DH524, DH530, andDH534) (Fig. 6). In
addition, these three MAbs were able to block binding of soluble
CD4 (sCD4) to Env protein in a competitive ELISA (Table 5).
Glycan dependence was assessed by measuring binding to gp120
proteins with and without mutations at well-described glycosyla-
tion sites (C.1086 gp120/C.1086 gp120 K160N and ConC gp120/
ConC gp120 N332A). None of the vaccine-elicited MAbs ap-
peared to depend on these glycosylation sites for Env binding (Fig.
6). Finally, MAbs were tested for the ability to block Env binding
of A32, an ADCC-mediating MAb directed against a C1 confor-
mational epitope. One IgG MAb (DH532) demonstrated 70%
blocking, suggesting conformational C1 specificity (Table 5). Two
IgA and two IgG vaccine-elicited breastmilkMAbswere unable to
be epitope mapped and presumably bind to conformational
epitopes (Fig. 6; Table 5).
i.n./i.m. Env vaccine-elicitedMAbs isolated frombreastmilk
B cells have diverse antiviral function. The neutralization po-
tency of the isolated milk Env-specific MAbs was assessed in
TZM-bl cells against four tier 1 viruses (C.MW965, B.SF162,
B.BaL.26, and B.MN.3), as well as the autologous tier 2 virus
C.1086. One V3-specific IgGMAb, DH535, neutralized all the tier
1 viruses tested but not the tier 2 autologous virus (Table 5). The
ability of MAbs to bind CEM.NKRCCR5 cells infected with C.1086
autologous virus was measured by immunofluorescence. Six
MAbs (2 IgA and 4 IgG) were observed to bind the surface of
C.1086-infected cells: DH524, DH530, DH534 (sCD4 blocking),
DH527 (V2), DH532 (A32 blocking), and DH535 (V3) (Table 5;
Fig. 7). Three of these MAbs also demonstrated ADCC activity
against CEM.NKRCCR5 cells coated with C.1086 gp120: DH527
(V2), DH532 (A32 blocking), and DH535 (V3) (Table 5; Fig. 8A).
Finally, the ability of the MAbs to inhibit binding of HIV
C.MW965 virions to epithelial cells was assessed (41). FourMAbs
(2 IgA and 2 IgG) blocked epithelial cell binding: DH524 and
DH534 (sCD4 blocking), DH525 (linear C4), and DH535 (V3)
(Table 5; Fig. 7). Thus, vaccine-elicited breast milk MAbs had a
wide array of antiviral functionalities which could contribute to
blocking viral infection at mucosal surfaces.
Postimmunization breastmilk has amoderate inhibitory ef-
fect onMAbADCCfunction. Since vaccine-elicited IgA inplasma
has previously been observed to interfere with the IgG effector
function of antibodies with the same specificity (13), we next
sought to determine whether the robust i.n./i.m.-elicited IgA re-
sponses in breast milk could inhibit ADCC activity by milk IgG.
Though ADCC was not observed in the unfractionated breast
milk of i.n./i.m. immunized animals, IgG purified from the same
breast milk was found to mediate a low level of ADCC activityT
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(approximate endpoint concentrations of 0.2 g/ml for A6E042
and 0.1g/ml for A6E088) (Fig. 8B). This result suggests a poten-
tial ADCC-blocking effect of the high-magnitude Env-specific IgA
response, but another possibility is the presence of an unidentified
blocking factor in milk. To further investigate this phenomenon
of ADCC inhibition, pre- and post-i.n./i.m. vaccination breast
milk was spiked with 10 g/ml of DH532 (the A32-blocking, vac-
cine-elicited milk MAb that mediates robust ADCC) or 15 ng/ml
of an ADCC MAb mix consisting of A32, 2G12, 7B2, and CH44
(Fig. 8C). Partial inhibition of ADCC effector function was ob-
served in the post-i.n./i.m. vaccination milk spiked with both
DH532 (29% inhibition) and the ADCC MAb mix (71% inhibi-
tion) but not in the pre-i.n./i.m. milk sample (Fig. 8D). Thus, the
high-magnitude IgA response or unidentified factors in post-i.n./
i.m. vaccination milk may account for the inability to detect
ADCC activity in unfractionatedmilk of i.n./i.m. Env-immunized
monkeys.
DISCUSSION
An inherent challenge in the prevention of breastmilkHIVMTCT
is elicitation of robust immune responses more potent than those
following natural infection. Breast milk from HIV-infected
women contains protective Env-specific antibodies (6, 8, 17, 42),
the presence of whichmakes development of a maternal HIV vac-
cine to enhance these preexisting responses an attractive strategy
to prevent breastfeeding transmission of HIV. In this study, we
gained further understanding of the isotypes, specificities, and
functions of HIV-specific breast milk antibody responses induced
by i.n./i.m. immunization and then compared them to previously
described responses that may be important to impede postnatal
transmission.
Although breast milk from both HIV-infected humans and
SIV-infected rhesus monkeys contains higher-magnitude Env-
specific IgG than IgA, in our recent analysis of breast milk anti-
body responses of women from the Breastfeeding Antiretrovirals
and Nutrition (BAN) study, only breast milk HIV envelope
gp140-specific IgA was associated with reduced risk of postnatal
HIV-1 acquisition (6, 7, 17). These results suggest that a maternal
vaccine with the ability to elicit robust IgA responses inmilk could
potentially be protective. It has traditionally proven very difficult
to induce Env-specific IgA inmucosal compartments byHIV vac-
cination (11). Yet, the combined systemic and mucosal vaccina-
tion regimen (i.n./i.m.) used in this study elicited remarkably
high-magnitude Env-specific IgA responses in breast milk, with a
concentration exceeding that in plasma. This provides proof of
principle that a vaccine can selectively elicit strong IgA responses
in the mammary compartments. It is intriguing that although se-
cretory IgA typically constitutes the majority of IgA in mucosal
secretions (43), following i.n. boost 2, SIgA represented only ap-
proximately 9% of the total Env-specific IgA in breast milk. This
finding indicates that the majority of Env-specific breast milk IgA
was either produced locally or passively transudated across epithe-
lial cells rather than secreted acrossmammary epithelia. However,
despite the observed differences in antibody response magnitude,
it is important to note that these differences were not statistically
significant given the small number of experimental animals.
In addition to the increased IgA-binding responses, i.n./i.m.
immunization also enhanced neutralization titers in breast milk.
Many innate factors in breast milk, such as tenascin C (TNC) and
lactoferrin, have been described to have an HIV-1-neutralizing
function (39, 44). To investigate whether an increased production
of these innate factors following immunization could contribute
to the observed increase in neutralization titers, we determined
the concentrations of tenascin C at multiple time points during
the immunization schedule. We observed that the concentrations
were quite low compared to human levels, far belowTNCneutral-
ization IC50 levels previously observed (39), and were similar be-
tween all animals and across all samples. These findings suggest
that the increase in neutralizing titer following immunization is
the result of an enhancement in Env-specific IgG and IgA re-
sponses rather than other innate factors. Interestingly, this inves-
tigation is the first to report the presence of TNC in breast milk of
rhesus monkeys.
Concordant with the high magnitude of Env-specific IgA in
FIG 6 Binding profile and determined specificities for 6 IgA and 6 IgG vaccine-elicited Env-specific MAbs isolated from breast milk B cells and selected for
functional characterization. EC50s (in g/ml) obtained by ELISA are shown. Tested antigens are grouped into categories (Env glycoproteins, Env regional
epitopes, CD4bs epitopes, and glycosylation mutants). NB, no binding detected.
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milk, a relatively high proportion of Env-specific breast milk B
cells were found to be IgA isotype. Previous studies have indicated
that IgA isotype B cells comprise 75 to 80%of allmammary gland-
associated B cells (45), and there is a body of evidence which sup-
ports the existence of a gut-mammary axis in primates by which
gut IgA-producing plasmablasts home to lactating mammary tis-
sue (46, 47). Quite counterintuitively, we and others have ob-
served that in the setting of chronic HIV infection, HIV Env-
specific memory B cells in breast milk are overwhelmingly IgG
isotype (9, 10). Therefore, the relatively high proportion (29%) of
Env-specific IgA-producing B cells induced by i.n./i.m. vaccina-
tion in breast milk is a novel finding and suggests that this vaccine
regimen led to trafficking of clonally proliferating Env-specific B
cells to the mammary compartment. The immune function of
these B cells in breast milk once ingested by the infant is poorly
understood. Intriguingly, activated mononuclear cells have been
observed to persist in the mammalian neonatal gut, bind to the
brush border, and infiltrate neonatal tissues (48, 49). This obser-
vation leaves open the possibility that ingested Env-specificmem-
ory B cells could serve as immune sentinels or further differentiate
into antibody-producing plasma cells in the infant GI tract.
Among our limited panel of 12 breast milk MAbs (6 IgA and 6
IgG), there was no clear association of antibody isotype with
epitope specificity, breadth, or function. As these MAbs were iso-
lated from a single immunized animal, it is unknownwhether our
results are representative of all immunized animals. Nevertheless,
our results clearly demonstrate that i.n./i.m. HIV vaccination can
induce IgA isotype memory B cells of diverse specificities in the
mucosal compartment and that vaccine-elicited IgA MAbs are
capable of mediating functions such as infected cell binding and
inhibition of viral binding to epithelial cells. Importantly, this
study is the first to isolate and characterize vaccine-elicited IgA
from mucosal Env-specific memory B cells. The significant
epitope and functional variability observed among ourMAbpanel
suggests that breast milk B cells are not restricted in their epitope
specificity. Given our previous discovery that a higher proportion
of breast milk B cells are gp120 directed in breast milk than in
plasma during chronic HIV-1 infection (9), we anticipate that
gp120 i.n./i.m. immunization of a chronically infected woman
could further enrich the proportion of gp120-specific B cells.
Interestingly, one of the breast milk IgG MAbs (DH535) was
able to mediate multiple effector functions. This V3-specificMAb
was determined to have broad tier 1 neutralization function, bind
to the surface of C.1086 infected cells, mediate ADCC, and inhibit
viral binding to epithelial cells. In a cohort of 248 HIV-infected
mothers, themagnitude of the V3-specific IgG inmaternal plasma
was recently associated with a decreased risk of perinatal MTCT
(50). The role of a V3-binding antibody in the prevention of post-
natal transmission has not clearly been established, yet it is possi-
ble that the polyfunctionality demonstrated by DH535 is required
to block mucosal HIV transmission. Indeed, a comparison be-
tween twoHIV clinical trials (RV144 and VAX003) demonstrated
that the ability of a vaccine to induce multiple, coordinated anti-
viral responses is associated with lower rates of HIV transmission
(51, 52).
The role of ADCC in protection against breast milk HIV trans-
mission remains unclear. While Mabuka et al. reported an associ-
ation between ADCC-mediating antibodies inmilk and a reduced
rate of transmission (8), in our analysis of the BAN cohort, ADCC
responses in milk were not associated with protection (17). Im-
portant differences between the cohorts of HIV-infected women
could explain these discordant results, including sample size, the
virus clade, and the maternal immune status. Surprisingly, com-
bined systemic/mucosal immunization did not elicit ADCC activ-
ity inmilk, thoughmultiple ADCC-mediatingMAbswere isolated
from breast milk B cells. As IgA blocking of ADCC effector func-
tion was demonstrated in the RV144 vaccine trial analysis, we
sought to determine if the lack of detectable ADCCactivity inmilk
was due to IgA interference. Purified IgG from post-i.n./i.m. vac-
cination breast milk was able to mediate low levels of ADCC ac-
tivity, suggesting a possible IgA-blocking effect. Furthermore,
when post-i.n./i.m. vaccination breast milk was spiked with
ADCC-mediating antibodies, therewas a reduction in the potency
of ADCC effector activity. Therefore, the high concentration of
Env-specific IgA in breast milk could be an important factor af-
fecting ADCC-mediated antibody function after i.n./i.m. vaccina-
tion. Nevertheless, the biological relevance of this ADCC blocking
for virus transmission remains to be determined.
FIG 7 Vaccine-elicited Env-specific MAbs from breast milk B cells bind in-
fected cells and prevent viral binding to epithelial cells. (A) 6MAbs (2 IgA and
4 IgG) demonstrated binding to the surface of C.1086 HIV-infected CEM.
NKRCCR5 cells. (B) 4 MAbs (2 IgA, 2 IgG) prevented C.MW965 from binding
to GI epithelial cells. Dashed lines indicate the cutoff for positivity, set at a
mean fluorescence intensity (MFI) of 100 for infected cell binding and a mean
percent inhibition (MPI) of 31 (mean plus 2 SD for negative control) for
inhibition of epithelial cell binding. The specificity of i.n./i.m.milkMAbs with
a positive result is denoted above the error bars.
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Since Env-specific IgA and ADCC activities have been associ-
ated with a reduced risk of postnatal HIV transmission, these re-
sponses are the benchmarks we have to judge the success or failure
of maternal HIV vaccination strategies to induce potentially pro-
tective immune responses in breast milk. It is remarkable that the
i.n./i.m. vaccination regimen both elicited a high level of Env-
specific breast milk IgA and induced local IgA isotype breast milk
B cells, which is a quite distinct immune response from that fol-
lowing natural infection. The ability of these robust vaccine-elic-
ited Env-specific IgA responses to prevent breast milk HIV trans-
mission should be further investigated in a nonhuman primate
model through infant oral SHIV challenge in the setting of expo-
sure to breast milk of a vaccinated dam. These studies would ad-
dress the potential in vivo protection of high-magnitude Env-spe-
cific IgA responses in breast milk and also interrogate any impact
of these IgA responses on ADCC functionality. Furthermore, a
nonhuman primate model has the potential to address the feasi-
bility of administering this proposed immunization regimen dur-
ing pregnancy, as well as the safety of an MVA prime for a devel-
oping fetus. If the procedure is proven efficacious and safe, such
studies would enable identification of novel immune correlates of
protection for postnatal HIV MTCT and would suggest that a
maternal vaccination strategy such as i.n./i.m. combined immu-
nization given during pregnancy has potential to curb the ongoing
pediatric HIV epidemic.
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